BRITISH MEDICAL JOURNAL VOLUME 285 21 AUGUST 1982 537 effect of obesity was negligible. It is surprising that the earlier reports from the Framingham Study5 (based on two-year incidence estimates) as well as the 10-year results from the Seven Countries Study4 failed to show-a convincing relation between obesity and coronary heart disease. A recent report from Framingham,"2 however, based on 26-year incidence data, identified obesity as an important and independent risk factor (especially in women).
(47%) were not smoking at one-year follow-up compared with 12 (21%) of the 58 subjects treated with placebo (p <0 025). By the most stringent criterion of outcome, 18 (31 %) subjects in the active treatment group and eight (14%) in the placebo group had not smoked at all from the start of treatment to follow-up at one year (p <005).
Subjects receiving the active gum experienced less severe withdrawal symptoms and rated their gum as more helpful than did the placebo group. Minor side effects were common but only gastric symptoms were more frequent with the active gum. Subjects receiving active gum used it for longer than those receiving placebo but most stopped using it within six months and only four (7%) developed longer-term dependence. The treatment group and with pretreatment cigarette consumption in the placebo group. A lower pretreatment blood nicotine value was the best predictor of success at one year (p <0 001) but there was no significant relation to cigarette consumption, sex, and social class.
The results clearly confirm the usefulness of nicotine chewing-gum as an aid to stopping smoking and imply a definite role for nicotine in cigarette dependence and withdrawal. Successful use of the gum requires careful attention to subjects' expectations and clear instructions on how to use it.
Introduction
Many smokers give-up smoking without any special help or treatment, but others have great difficulty and fail many times. The first smoking-cessation clinic was started in Stockholm in 1955.1 Since then there has been an intensive search for an effective treatment for dependent smokers. Simple support and encouragement, given individually or in groups, has a success rate of around 15-25% abstinent at one-year follow-up.2 Numerous other methods have been tried, including tranquillisers,3 lobeline,4 electric aversion therapy,5 rapid smoking,6 hypnosis,7 and, more recently, acupuncture.8 None of these methods, however, has been found to have a specific effect over and above the attention-placebo element inherent in any treatment.
We have reported encouraging results from the use of nicotine chewing-gum (Nicorette) in our smokers' clinic. In a comparative study the success rate of smokers who received the gum was 380% abstinent at one year of follow-up compared with only 14% of those who had had intensive psychological treatment. 9 We now report the results of a randomised double-blind placebocontrolled trial of the gum with one-year follow-up and biochemical validation of reported abstinence from smoking.
The active gum contained 2 mg nicotine and was identical with the commercially available preparation. The placebo gum contained 1 mg nicotine and its biological availability was reduced by the lack of an alkaline buffer to promote absorption through the buccal mucosa. The placebo was designed in this way to mimic the nicotine taste of the active gum without providing an effective pharmacological dose. In pretrial tests the placebo gum did produce appreciable plasma nicotine concentrations with excessive chewing (117 nmol/l (19 ng/ ml) when chewed half-hourly for four hours). This suggests that anyone chewing 20 or more placebo gums a day would get a pharmacologically effective dose. The study could therefore be described as a dose-response study. Whatever terminology is preferred, there is no doubt that the "placebo" provided a fairly stringent test of the pharmacological role of nicotine in the efficacy of the active gum. Both active and placebo gums were packed identically and labelled as 2 mg Nicorette.
A total of 116 subjects were entered into the trial. All subjects were given the same instructions about the gum. They were told that it contained nicotine which would be absorbed through the lining of the mouth as it was chewed, and that it would reduce the craving for cigarettes and help to relieve other withdrawal symptoms. They were warned that it might take a few days to get used to the taste, and that they should not expect it to be a miracle cure that removed the necessity for them to work very hard at stopping. They were encouraged to stop smoking completely on the first day of treatment and told to chew a piece of gum whenever the desire to smoke was particularly strong. No restrictions were placed on the number of gums to be chewed each day. It was recommended that they should use the gum for at least three months before attempting to do without it.
Group meetings were held weekly for one hour for the first six weeks. Attendance was similar in those receiving the active and placebo gums, with 28 and 29 subjects respectively attending three or more meetings. Thereafter subjects attended as needed to collect gum and for follow-up at three months, six months, and one year. At the oneyear follow-up claims of abstinence were validated by measurement of expired air carbon monoxide concentrations. There were no cases of deception. In six subjects assigned to active gum and six assigned to placebo biochemical validation was not done but confirmatory reports were obtained from friends or relatives.
At each attendance subjects completed ratings of withdrawal symptoms, acceptability of their gum, and a check list of potential side effects. They were also given cards to record daily consumption of gum and cigarettes.
Statistical analyses were based on the binomial test, X2 test, and t test. Two-sided tests were used except for the analysis of outcome, where the one-sided hypothesis that the active gum was superior to the placebo was tested.
Results

OUTCOME
The figure shows the success rates of the active and placebo gums. A significant advantage for the active gum emerged as early as two weeks after the start of treatment, when 39 subjects assigned to the active gum were not smoking as compared with only 26 assigned to the placebo (Z = 2 24; p < 0 025). At one year 27 (47%) of those given the active gum were abstinent as compared with 12 (21 %) of those given the placebo (see table II) .
The results were unusual in that there were more subjects abstinent in the active-treatment group at one year than at six months, indicating that several subjects who had relapsed at the earlier point stopped smoking again before one year. Table II therefore gives the result of applying more stringent criteria of success to supplement the conventional analysis. Whichever criterion of success was applied the active gum was clearly more effective than the placebo. Of those abstinent at the one-year follow-up, six in the activetreatment group and two in the placebo group were still using the gum. When for the sake of extreme stringency these subjects were excluded from the one-year abstainers, the active gum retained its clear-cut advantage over placebo with 21 (360o) abstinent at one year compared with 10 (170o) of the placebo group (Z= 210; p<0 05). At a mean of 22 months after starting treatment, five of the six subjects given the active gum were still abstinent and three were still using the gum. Both subjects given the placebo had relapsed to smoking. The figure shows that the main effect of the active gum was to enable more subjects to stop smoking initially. There were also fewer relapses in the active-treatment group, although this failed to reach statistical significance. In the active-treatment group 12 of the 39 subjects abstinent at two weeks had relapsed to smoking at one year, compared with 14 of the 26 in the placebo group (X2 =2-57; df= 1; NS).
QUANTITY AND DURATION OF GUM USE
Use of the active gum was greater than the placebo at every stage of treatment and follow-up both in terms of the proportion of subjects who were using it and the number of pieces they were chewing a day. The differences, however, were statistically significant only at three and six months (table III) . Of the seven subjects using active gum and three using placebo gum at the one-year follow-up, only four, all in the active group, had used it continuously throughout the year. The incidence of dependence on the active gum was therefore 7°', and there were no such cases in the placebo group.
Among those who were not smoking at one month there was a 21 AUGUST 1982 (table IV) . They were mainly non-specific effects of heavy chewing. Only in the case of hiccups, indigestion or stomach ache, and feeling sick was the incidence substantially higher and therefore interpretable as specific side effects of the active gum. In most cases these symptoms were mild and transient. In no cases were side effects cited as a cause for discontinuing the gum.
ACCEPTABILITY OF GUM
Ten subjects in the active-treatment group and 13 in the placebo group did not attend the first meeting after the start of treatment. We do not know whether this was due to dislike of the gum, disappointment with its efficacy, or other reasons. Among the remainder the active group rated the gum as significantly stronger (p < 0 05) and more helpful (p < 0 05) than the placebo group. Both groups rated the gum as moderately satisfying and slightly unpleasant tasting, and these ratings did not differ significantly between the two groups when averaged over the first six weeks of treatment. In the first week, however, the active group rated their gum as tasting more unpleasant than did the placebo group (p < 0 05), a difference which disappeared by the second week. By the second week the active group found the gum more satisfying than did the placebo group (p < 0 05).
WITHDRAWAL SYMPTOMS
Since the pattern of attendance at weekly treatment sessions did not differ between the active-treatment and placebo groups, each subject's ratings of withdrawal symptoms over the first six weeks of treatment were averaged. Subjects who received the active gum experienced less severe withdrawal symptoms than the placebo group. They felt less irritable (p < 0 05), less sleepy (p < 0 01), and less hungry (p < 0 05). Differences between the groups in ratings of tenseness, feeling miserable, and difficulty doing without cigarettes also favoured the active gum but did not reach statistical significance. The active group, however, also rated themselves as less alert but this difference was not significant.
CHARACTERISTICS OF SUBJECTS AND OUTCOME
The relation of the variables listed in table I to outcome at the one-year follow-up was similar in the active-treatment and placebo groups, so that the two groups were combined to provide 39 successes and 77 failures. The successes tended to be older (mean ages 43 v 38 years; p < 0 05) and to have lower pretreatment carboxyhaemoglobin values (mean 60%0 v 76%o; p< 001) and lower plasma nicotine concentrations (mean 172 0 nmol/l (27-9 ng/ml) v 229-3 nmol/l (37 2 ng/ml); p <0001). Their mean pretreatment daily cigarette consumption was also lower (26 3 v 29 9) but this difference was not statistically significant. Social class and sex had no relation to outcome. The success rate among the men was 37% (19/52) compared with 31% (20/64) for the women (Xa2=0-36; NS).
Discussion
Treatment with the active nicotine chewing-gum achieved results that were substantially better than with the placebo. Success rates, based on three different criteria, were more than double those obtained with placebo. By the conventional criterion of smoking status at follow-up 47% of the subjects in the active-treatment group were abstinent at one year compared with 21% of the subjects given placebo. By the criterion of abstinence at the end of treatment and at six months and one year the success rates were 38% and 16% respectively, and when based on lapse-free abstinence throughout the year from the first week of treatment to the one-year follow-up they were 31%o and 14% respectively. The differences were statistically significant in all three cases and were of a similar order to our earlier study, which obtained a 38% success rate (conventionally defined) with nicotine chewing-gum compared with 14% for intensive psychological treatments.9 In both studies the active gum alone gave results that were well above the range (about 15-25 %) reported for all other methods.2
Our study was unusual in showing a better result at one year than at six months. This was because some subjects who relapsed returned for further treatment. This response contrasts with studies of other treatment methods, in which those who relapse tend to avoid returning even for follow-up. The tendency for those treated with nicotine gum to be more likely to return for a second course if they relapse may be a further reflection of its greater efficacy.
The rigorous design of our study with randomised allocation, double-blind placebo control, success rates based on all who started -treatment, biochemical validation of reported abstinence, and the fact that the placebo provided nicotine to taste but with low biological availability all make it difficult to see how the gum could have achieved its effect other than by a specific action of the nicotine it provided. This further suggests an important role for nicotine in maintaining the habit of dependent smokers. That the active gum was significantly more effective in relieving withdrawal symptoms also supports the view that they may be caused partly by nicotine deprivation.
Another finding also has possible implications for the role of nicotine in smoking. This is that the extent of gum use was significantly related to pretreatment plasma nicotine values but not to cigarette consumption in those given the active gum, whereas the reverse was true for those using the placebo. This suggests that the active gum was fulfilling a pharmacological need while the placebo may have been acting more as an oral substitute. The pharmacological role of nicotine is also supported by the fact that 7% of those assigned to receive the active gum developed some degree of dependence on it, while there were no instances of dependence on the placebo.
On the practical side, the active gum was apparently more effective in helping smokers to stop smoking during the first four weeks of treatment than in reducing the tendency to relapse thereafter. Other studies have found higher rates of long-term success among those who continued using the gum for longer periods.9 1 While it was realised that this may have been attributable to self-selection with people continuing to chew while they were successfully keeping off cigarettes but giving up the gum as soon as they relapsed to smoking, this finding was nevertheless used as a reason for suggesting that longer-term use of the gum might improve outcome.'4 That our placebo group also showed a similar trend in this direction suggests that further study is needed to establish the optimal duration of gum use.
We emphasise that the high success rate achieved in this study was not necessarily due to the gum alone. The subjects had six group meetings with an experienced therapist. Above all they were given careful instructions on what they might realistically expect from the gum and how to use it correctly. This no doubt accounted for the lack of more than mild and transient side effects. That the active gum was initially more unpleasant to taste but subsequently became more satisfying points to the importance of encouraging subjects to persist with it for at least two weeks.
We conclude that after more than 20 years of unsuccessful research into all kinds of treatment methods for smokers, nicotine chewing-gum given to well-motivated smokers in a clinic setting is the first treatment to have been developed that has a specific effect over and above that attributable to an attention-placebo response. That it is also the first treatment to provide effective nicotine substitution has important implications for the role of nicotine in cigarette dependence.
(Accepted 24 June 1982) THE OAK iS so well known (the timber thereof being the glory and safety of this nation by sea) that it needs no description.
Jupiter owns the tree. The leaves and bark of the Oak, and the acorn cups, do bind and dry very much. The inner bark of the tree, and the thin skin that covers the acorn, are most used to stay the spitting of blood, and the bloody-flux. The decoction of that bark, and the powder of the cups, do stay vomitings, spitting of blood, bleeding at the mouth, or other fluxes of blood, in men or women; lasks also, and the nocturnal involuntary flux of men. The acorn in powder taken in wine, provokes urine, and resists the poison of venomous creatures. The decoction of acorns and the bark made in milk and taken, resists the force of poisonous herbs and medicines, as also the virulency of cantharides, when one by eating them hath his bladder exulcerated, and voids bloody urine. Hippocrates saith, he used the fumes of Oak leaves to women that were troubled with the strangling of the mother; and Galen applied them, being bruised, to cure green wounds. The distilled water of the Oaken bud, before they break out into leaves is good to be used either inwardly or outwardly, to assuage inflammations, and to stop all manner of fluxes in man or woman. The same is singularly good in pestilential and hot burning fevers; for it resists the force of the infection, and allays the heat: It cools the heat of the liver, breaking the stone in the kidneys, and stays women's courses. The decoction of the leaves works the same effects. The water that is found in the hollow places of old Oaks, is very effectual against any foul or spreading scabs. The distilled water (or concoction, which is better) of the leaves, is one of the best remedies that I know of for the whites in women. (Nicholas Culpeper (1616-54) The Complete Herbal, 1850.)
